OVdialogue – consider joining our team in the role of Community Champion. Over a few hours each week, you would be part of a team that helps connect people, support conversations and are thought leaders for OVdialogue. This is your opportunity to give back to those who have/continue to support you through the tough times, share your unique experiences, and help celebrate successes. For more details of what this entails, please reach out to @Mfallis (mfallis@ovariancanada.org).
Stay tuned for more details, and feel free to share your thoughts below. Let’s make this community even stronger!
Patient input needed by June 19th to help secure funding for pembrolizumab (Keytruda) in Canada
Hi everyone,
Short timeline here, but exciting news to share regarding pembrolizumab (Keytruda) for ovarian cancer …
Merck Canada, the manufacturer of pembrolizumab (Keytruda) has applied to the Canadian Agency for Drugs and Technologies in Health (CADTH) to have this treatment covered for individuals who have been diagnosed with an MIS-H/dMMR cancer, including ovarian cancer. Colorectal Cancer Resource & Action Network (CCRAN) is coordinating and preparing a Patient Submission to support this application.
Ovarian Cancer Canada is supporting CCRAN by spreading the word to our ovarian cancer community: If you or someone you know has been diagnosed with an MIS-H/dMMR ovarian cancer, has received pembrolizumab (Keytruda) and is interested in taking part in an interview with CCRAN staff so that your experience with this treatment can be considered in the drug approval process, please contact cassandra.m@ccran.org or 833-792-2726 ext. 1001 by June 19th to get involved.
All the best!